一种带抗反流瓣膜的新型食管支架性能的III期、多中心、前瞻性、单盲、非劣效性、随机对照试验(附视频)
这项III期多中心前瞻性单盲非劣效随机对照试验将60例需跨胃食管连接处放置自膨式金属支架的恶性吞咽困难患者随机分为无瓣膜支架组和带三尖瓣抗反流瓣膜支架组,发现带瓣膜支架在缓解吞咽困难方面与无瓣膜支架等效,未增加不良事件风险,但两组胃食管反流病症状评分相似,作者建议进行客观评估研究。
要点
- 带瓣膜支架与无瓣膜支架在改善吞咽困难方面效果相当(71% vs 74%)。
- 带瓣膜支架未增加不良事件风险,吸入性肺炎发生率两组无显著差异。
- 两组胃食管反流病症状评分相似,瓣膜效果可能被质子泵抑制剂掩盖。
核心结论
- 带瓣膜支架在缓解吞咽困难方面与无瓣膜支架等效,瓣膜的存在未增加不良事件风险。
- 两组支架的胃食管反流病症状评分相似,提示瓣膜可能无效或所有患者使用质子泵抑制剂掩盖了症状。
- 作者建议进行诸如透视和/或pH/阻抗等客观评估的研究。
研究设计与样本
- III期、多中心、前瞻性、单盲、非劣效性、随机对照试验。
- 纳入需跨胃食管连接处放置自膨式金属支架的恶性吞咽困难患者60例,随机分为无瓣膜支架组30例和带瓣膜支架组30例。
- 无瓣膜支架组平均年龄67±13岁,带瓣膜支架组平均年龄65±12岁。
- 随访24周。
主要发现
- 基线吞咽困难评分:无瓣膜支架组2.5±0.8,带瓣膜支架组2.5±0.8;基线GERD-HRQL评分:无瓣膜支架组11.1±8.2,带瓣膜支架组12.8±8.3。
- 从严重吞咽困难改善至中度至无吞咽困难的患者比例:无瓣膜支架组71%,带瓣膜支架组74%,95%置信区间1.93 [-17.8至21.7]。
- 平均GERD-HRQL评分改善:带瓣膜支架组7.4±10.2分,无瓣膜支架组5.2±8.3分(P=0.96)。
- 吸入性肺炎发生率:无瓣膜支架组3.3%,带瓣膜支架组6.9%(P=0.61)。
- 支架移位率:无瓣膜支架组33%,带瓣膜支架组48%(P=0.29);带瓣膜支架组有2例自发性断裂;两组均无穿孔、食物嵌塞或支架相关死亡。
局限性
- 作者指出胃食管反流病症状评分相似可能提示瓣膜无效或所有患者使用质子泵抑制剂掩盖了症状,需进一步研究。
- 作者建议进行透视和/或pH/阻抗等客观评估的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Self-expanding metal stents (SEMSs) when deployed across the gastroesophageal junction (GEJ) can lead to reflux with risks of aspiration. A SEMS with a tricuspid antireflux valve (SEMS-V) was designed to address this issue. The aim of this study was to evaluate the efficacy and safety of this stent. METHODS: A phase III, multicenter, prospective, noninferiority, randomized controlled trial was conducted on patients with malignant dysphagia requiring SEMSs to be placed across the GEJ. Patients were randomized to receive SEMSs with no valve (SEMS-NV) or SEMS-V. Postdeployment dysphagia score at 2 weeks and Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) questionnaire score at 4 weeks were measured. Patients were followed for 24 weeks. RESULTS: Sixty patients were randomized (SEMS-NV: 30 patients, mean age 67 ± 13 years; SEMS-V: 30 patients, mean age 65 ± 12 years). Baseline dysphagia scores (SEMS-NV, 2.5 ± .8; SEMS-V, 2.5 ± .8) and GERD-HRQL scores (SEMS-NV, 11.1 ± 8.2; SEMS-V, 12.8 ± 8.3) were similar. All SEMSs were successfully deployed. A similar proportion of patients in both arms improved from advanced dysphagia to moderate to no dysphagia (SEMS-NV, 71%; SEMS-V, 74%; 95% confidence interval, 1.93 [-17.8 to 21.7]). The dysphagia scores were also similar across all follow-up time points. Mean GERD-HRQL scores improved by 7.4 ± 10.2 points in the SEMS-V arm and by 5.2 ± 8.3 in the SEMS-NV group (P = .96). The GERD-HRQL scores were similar across all follow-up time points. Aspiration pneumonia occurred in 3.3% in the SEMS-NV arm and 6.9% in the SEMS-V arm (P = .61). Migration rates were similar (SEMS-NV, 33%; SEMS-V, 48%; P = .29). Two SEMS-V spontaneously fractured. There was no perforation, food impaction, or stent-related death in either group. CONCLUSIONS: The SEMS-V was equally effective in relieving dysphagia as compared with the SEMS-NV. Presence of the valve did not increase the risks of adverse events. GERD symptom scores were similar between the 2 stents, implying either that the valve was not effective or that all patients on proton pump inhibitors could have masked the symptoms of GERD. Studies with objective evaluations such as fluoroscopy and/or pH/impedance are recommended. (Clinical trial registration number: NCT02159898.).
引用
- Dua KS, DeWitt JM, Kessler WR, et al. A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video). Gastrointest Endosc. 2019. PMID: 30684601. doi:10.1016/j.gie.2019.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。